title: Bolus fluorouracil and leucovorin with oxaliplatin as first-line treatment in metastatic colorectal cancer.
abstract: OBJECTIVE
  A phase II trial investigated the activity and toxicity of a bolus administration schedule of oxaliplatin, fluorouracil (5-FU), and leucovorin (LV) therapy in patients with untreated advanced colorectal cancer.
  
  
  METHODS
  Forty-five patients in this multicenter, open, nonrandomized study received oxaliplatin 130 mg/m(2) on the first day of each course and 5-FU and LV 350 mg/m(2) and 20 mg/m(2), respectively, as a daily bolus for 5 days, every 21 days, for a maximum of six courses.
  
  
  RESULTS
  Partial responses occurred in 18 patients, giving an intent-to-treat response rate of 40.0%. Median time to response was 12.7 weeks; median duration of response was 18.4 weeks. Median progression-free survival was 5.9 months; median survival was 14 months. The independent prognostic factors for improved overall survival were good performance status and negative carcino-embryonic antigen blood level. Incidences of adverse effects were reduced after the 5-FU dose was reduced to 300 mg/m(2). Reversible neurologic toxicity occurred in 44.4% of patients.
  
  
  CONCLUSIONS
  Bolus administration of oxaliplatin, 5-FU, and LV as first-line therapy for untreated advanced colorectal cancer is efficacious and safe. In addition to a more favorable safety profile, the 300 mg/m(2) dosage offered improved dose-intensity compared with the initial dosage.
authors: Department of Oncology, Infermi Hospital, Via Settembrini 2, 47900 Rimini, Italy. aravaiol@austrn.net
authors: Alberto
authors: A
authors: Ravaioli
authors: Maurizio
authors: M
authors: Marangolo
authors: Enzo
authors: E
authors: Pasquini
authors: Andrea
authors: A
authors: Rossi
authors: Dino
authors: D
authors: Amadori
authors: Giorgio
authors: G
authors: Cruciani
authors: Davide
authors: D
authors: Tassinari
authors: Giovanni
authors: G
authors: Oliverio
authors: Petros
authors: P
authors: Giovanis
authors: Daniele
authors: D
authors: Turci
authors: Federica
authors: F
authors: Zumaglini
authors: Mario
authors: M
authors: Nicolini
authors: Ilaria
authors: I
authors: Panzini
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D002955:Leucovorin / Q000008:administration & dosage / Q000009:adverse effects; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D002955:Leucovorin; D005472:Fluorouracil